Abstract Number: 2756 • 2014 ACR/ARHP Annual Meeting
Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study
Background/Purpose: IL-1 blocking therapy shows promise in the treatment of Behçet’s eye disease, but its effect on mucocutaneous manifestations is unknown. Methods: 6 patients with…Abstract Number: 2507 • 2014 ACR/ARHP Annual Meeting
Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret®)?
Background/Purpose 458 patients with rheumatoid arthritis (RA) and inadequate response to traditional DMARDs alone and/or TNFα blocking agents were treated with the IL-1 receptor antagonist…Abstract Number: 2283 • 2014 ACR/ARHP Annual Meeting
Steroid-Sparing Effect of Anakinra (Kineret®) in the Treatment of Patients with Severe Cryopyrin-Associated Periodic Syndrome
Background/Purpose Cryopyrin-Associated Periodic Syndromes (CAPS) include a group of rare inherited autoinflammatory diseases consisting of FCAS, Muckle-Wells Syndrome and the most severe form, NOMID. Reduction…Abstract Number: 1972 • 2014 ACR/ARHP Annual Meeting
Analysis of Anakinra in Primary Human Cell Systems Reveals an in Vitro Signature for Skin-Related Side Effects
Background/Purpose The therapeutic options for treatment of rheumatic diseases have grown and now include a variety of inflammatory pathway inhibitors, with diverse mechanisms, but having…Abstract Number: 1243 • 2014 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome Complicating Adult Onset Still’s Disease – Single Center Experience and Literature Review
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a life threatening complication typically associated with hematologic malignancies and infections. HLH, also referred to as macrophage activation syndrome (MAS),…Abstract Number: 1242 • 2014 ACR/ARHP Annual Meeting
Switching Biologic Agents in Refractory Adult-Onset Still’s Disease: Efficacy and Safety in a Cohort of 20 Patients at a Single Referral Center
Background/Purpose No data is available on the long-term clinical outcome of Adult-Onset Still's Disease (AOSD) patients treated with biological drugs, nor on the efficacy and…Abstract Number: 1230 • 2014 ACR/ARHP Annual Meeting
Efficacy of Interleukin-1 Targeting Drugs in Familial Mediterranean Fever Patients
Background/Purpose Familial Mediterranean fever (FMF) is an autosomal-recessive autoinflammatory disorder characterized by recurrent episodes of fever accompanied by sterile peritonitis. The most devastating complication of…Abstract Number: 328 • 2014 ACR/ARHP Annual Meeting
Etanercept, Abatacept and Anakinra Treatment Ameliorates Inflammation and Pain in a Novel Mono-Arthritic Multi-Flare Model of Streptococcal Cell Wall Induced Arthritis: Further Characterization in a Rodent Model of Collagen Induced Arthritis
Background/Purpose: We developed a novel mono-arthritic multi-flare Rat Streptococcal Cell Wall (SCW) model which captures certain aspects of disease with flares and remission of inflammation…Abstract Number: 2028 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologic Agents In Adult-Onset Still’s Disease: A Long-Term Follow-Up Of 19 Patients At a Single Referral Center
Background/Purpose: No data comparing the long-term outcome of Adult-Onset Still’s Disease (AOSD) patients treated with different biological drugs is currently available. We evaluated the efficacy…Abstract Number: 1191 • 2013 ACR/ARHP Annual Meeting
Low-Dose Anakinra Is Effective For The Prophylaxis Of Acute Episodes Of Inflammation In Severe Tophaceous Gout
Background/Purpose: anakinra has been used off-label for the treatment of severe episodes of acute inflammation (EAIs) in gout. Only a retrospective series of 3 patients…Abstract Number: 2036 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy For Relapsing Polychondritis: Old and New Efficacy Indices
Background/Purpose: The inflammatory milieu in affected tissues from Relapsing Polychondritis (RP) is rich in TNF-α, IL-1-β and IL-6. Cytokine-targeted biologic therapies has therefore been proposed…Abstract Number: 2031 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Anakinra in Patients with Deficiency of Interleukin-1 Receptor Antagonist
Background/Purpose: Deficiency of interleukin-1 receptor antagonist (DIRA) is a neonatal-onset autoinflammatory syndrome caused by mutations in IL1RN gene and clinically characterized by a perinatal onset…Abstract Number: 1923 • 2012 ACR/ARHP Annual Meeting
Biologics in Relapsing Polychondritis: A Single Center Case-Series
Background/Purpose: First-line treatment for relapsing polychondritis (RP) is costicosteroids (CS). Dapsone and methotrexate have been proposed as second-line therapies. Only few reports have been published…Abstract Number: 747 • 2012 ACR/ARHP Annual Meeting
Familial Mediterranean Fever: Inhibition of IL-6 Signalling As a New Therapeutic Option in a Frequent Autoinflammatory Syndrome.
Background/Purpose: Familial Mediterranean Fever (FMF) is the most prevalent episodic fever syndrome with more than 100.000 affected individuals worldwide. Colchicine is the established first-line therapy…Abstract Number: 179 • 2012 ACR/ARHP Annual Meeting
Evaluation of Anakinra Therapy in Seven Adults After Suboptimal Response to Etanercept Therapy for Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome
Background/Purpose: Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome (TRAPS) is an autoinflammatory disease inherited in an autosomal dominant fashion. TRAPS develops secondary to mutations in…
ACR Meeting Abstracts